Hameed Muhammad Y, Gul Maryam, Chaudhry Abbas, Muzaffar Huma, Sheikh Mubashir, Chee Winson, Ayyash Sondos, Ayyash Jenna, Al-Hindi Mohannad, Shahare Humam, Chaudhry Ammar
College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72223, USA.
Crescent Theranostics, Anaheim, CA 982902, USA.
Cancers (Basel). 2024 Aug 31;16(17):3039. doi: 10.3390/cancers16173039.
Prostate cancer, a leading cause of cancer-related mortality among men, is characterized by complex genetic and epigenetic alterations, dysregulation of oncogenic pathways, and a dynamic tumor microenvironment. Advances in molecular diagnostics and targeted therapies have significantly transformed the management of this disease. Prostate-specific membrane antigen (PSMA) has emerged as a critical biomarker, enhancing the precision of prostate cancer diagnosis and treatment. Theranostics, which integrates PSMA-targeted imaging with radioligand therapies, has shown remarkable efficacy in detecting and treating advanced prostate cancer. By leveraging the dual capabilities of PSMA-based diagnostics and therapeutic agents, theranostics offers a personalized approach that improves patient outcomes. This comprehensive review explores the latest developments in PSMA-targeted theranostics and their impact on the future of prostate cancer management, highlighting key clinical trials and emerging therapeutic strategies.
前列腺癌是男性癌症相关死亡的主要原因之一，其特征在于复杂的基因和表观遗传改变、致癌途径失调以及动态的肿瘤微环境。分子诊断和靶向治疗的进展显著改变了这种疾病的管理方式。前列腺特异性膜抗原（PSMA）已成为一种关键的生物标志物，提高了前列腺癌诊断和治疗的精准度。将PSMA靶向成像与放射性配体疗法相结合的诊疗一体化技术，在检测和治疗晚期前列腺癌方面已显示出显著疗效。通过利用基于PSMA的诊断和治疗药物的双重功能，诊疗一体化技术提供了一种个性化方法，可改善患者预后。这篇综述探讨了PSMA靶向诊疗一体化技术的最新进展及其对前列腺癌管理未来的影响，重点介绍了关键临床试验和新兴治疗策略。
